Skip to content

Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder - Panik-Extinktion-Cycloserin-fMRI

Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder - Panik-Extinktion-Cycloserin-fMRI

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-023044-32-DE
Enrollment
96
Registered
2011-03-21
Start date
2011-08-10
Completion date
Unknown
Last updated
2014-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

panic disorder and agoraphobia

Interventions

Sponsors

Charité Universitaetsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Written consent (according to § 40 AMG (1) 3 b) - diagnosis of panic disorder and / or agoraphobia, severity of disease after at least CGI > 3 "mildly ill" - age: 18-65 years - Sufficient ability to communicate with the investigators to answer questions and fill in questionnaires or scales - Negative pregnancy test and safe contraception during the study (defined as the Pearl Index =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Known overreaction after ingestion of D-cycloserine - placement in an institution of judicial or administrative order (according to § 40 AMG (1) 4) - Other psychiatric disorders such as schizophrenia, substance dependence, dementia - Acute Suicidality - epilepsy or other diseases of the central nervous system (brain tumor, encephalitis) - internal diseases such as severe hypertension, congestive heart failure, Zn acute myocardial infarction, cardiac arrhythmia of grade IV or V according to Lown, severe liver or kidney dysfunction, insulin-dependent diabetes, disorders of hematopoiesis - Pregnancy or lactation - changes a psychopharmacotherapy within the last 2 weeks, discontinuation of treatment with psychotropic drugs less than 1 week prior to the study or last-time use of benzodiazepines for less than 4 days - Short-term disturbances of the past day / night cycle - Disorder-specific psychotherapy - Participation within the last month prior to enrollment or during participation in the panic-Cyclo study in another study, AMG - lack of capacity to consent - Medical circumstances which exclude an fMRI study (eg existence of ferromagnetic metal or pacemakers).

Design outcomes

Primary

MeasureTime frame
Main Objective: Changes in neuronal activation patterns of the three measurements of time in the "Extinction Circuit" (eg amygdala, hippocampus, medial prefrontal cortex);Secondary Objective: Influence of DCS on other relevant neural networks (eg space perception and processing), on Habituation to the scanner measured using fMRI questionnaire, neuropsychological parameter (eg memory) and on conditioning and extinction (contingency interview: ratings of CS + / CS, EDA reaction and behavioral learning curves as a measure of the conditioned response as well as modulation of a neural prediction error signal). ;Primary end point(s): Changes in neuronal activation patterns of the three measurements of time in the "Circuit Extinction"(eg amygdala, hippocampus, medial prefrontal cortex)

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026